Deep Vein Thrombosis / Pulmonary Embolism (VTE) — RepurpOS

Disease overview

Alterations

105

Molecular (A)

100

Clinical (B–E)

Direct drugs

Via biomarker

100

Natural agents

Natural products

Merged ranked

135

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Examine.com, PubMed NP Literature · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

Without anticoagulation: DVT progresses to PE in 30-50%; massive PE has 30%+ mortality without treatment; spontaneous resolution of small PE in 30-40% but recurrence risk high

Best-intervention remission

DOACs (rivaroxaban, apixaban): equal or superior efficacy to warfarin with 50% reduction in major bleeding; catheter-directed thrombolysis for large DVT: rapid thrombus resolution but unclear long-term benefit on PTS (ATTRACT trial); acute massive PE with hemodynamic compromise: systemic thrombolysis reduces mortality 55-65%

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Moderate — DOACs have largely replaced warfarin; remaining gap is in chronic anticoagulation decision-making and post-VTE care

Primary barrier

practice

Barrier detail: DOAC superiority is established but warfarin persistence remains common in patients with mechanical valves (where DOACs are contraindicated) and in some LMIC settings; duration of anticoagulation after unprovoked VTE is an individualised decision poorly standardised; post-thrombotic syndrome (PTS) prevention with compression is rarely implemented

Last SoC change: 2023 — betrixaban/edoxaban expanding in specific populations; 2020 Andexanet alfa (reversal agent for FXa inhibitors) established; DOACs first-line since 2012-2014 (EINSTEIN, AMPLIFY trials); warfarin standard since 1954

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0005399 · ORPHA: ORPHA:82

Right to Try Relevance

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Venous Thromboembolism may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

Phase 3: 13, Phase 2: 3

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

105

Actionable

Pipeline Compounds (Top 6)

Abelacimab, Atorvastatin, Bemiparin, Enoxaparin, Fondaparinux, Heparin

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

Showing 80 of 105 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Thromboembolism	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
A4GALT alpha 1,4-galactosyltransferase (P1PK blood group)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ABCA5 ATP binding cassette subfamily A member 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ABCA6 ATP binding cassette subfamily A member 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ABO ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AFAP1 actin filament associated protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AK5 adenylate kinase 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ANGPT1 angiopoietin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ANO2 anoctamin 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
APOE apolipoprotein E	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARHGAP24 Rho GTPase activating protein 24	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ASH2L ASH2 like, histone lysine methyltransferase complex subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATP1B1 ATPase Na+/K+ transporting subunit beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
All cause mortality	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
C4BPA complement component 4 binding protein alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
C4BPB complement component 4 binding protein beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CALCRL calcitonin receptor like receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CATSPERB catsper channel auxiliary subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDH6 cadherin 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CELSR2 cadherin EGF LAG seven-pass G-type receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CLEC4M C-type lectin domain family 4 member M	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CPNE8 copine 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CPS1 carbamoyl-phosphate synthase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CSTPP1 centriolar satellite-associated tubulin polyglutamylase complex regulator 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP4V2 cytochrome P450 family 4 subfamily V member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DCAF6 DDB1 and CUL4 associated factor 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DGKZ diacylglycerol kinase zeta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EPHA3 EPH receptor A3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERAP2 endoplasmic reticulum aminopeptidase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
F10 coagulation factor X	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
F11 coagulation factor XI	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
F2 coagulation factor II, thrombin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
F5 coagulation factor V	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
F9 coagulation factor IX	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGA fibrinogen alpha chain	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGB fibrinogen beta chain	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGG fibrinogen gamma chain	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FOLH1 folate hydrolase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FUT2 fucosyltransferase 2 (H blood group)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GDF5 growth differentiation factor 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GP6 glycoprotein VI platelet	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRK5 G protein-coupled receptor kinase 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HIC1 HIC ZBTB transcriptional repressor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HNF4A hepatocyte nuclear factor 4 alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HSPA4 heat shock protein family A (Hsp70) member 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL1RN interleukin 1 receptor antagonist	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL6R interleukin 6 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Incidents of major VTE	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
JAZF1 JAZF zinc finger 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JMJD1C jumonji domain containing 1C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KIFAP3 kinesin associated protein 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KLKB1 kallikrein B1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KNG1 kininogen 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LIFR LIF receptor subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LRP4 LDL receptor related protein 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MADD MAP kinase activating death domain	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAP3K2 mitogen-activated protein kinase kinase kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND4 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MYO7B myosin VIIB	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NCAM2 neural cell adhesion molecule 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NUGGC nuclear GTPase, germinal center associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
OR4A8 olfactory receptor family 4 subfamily A member 8 (gene/pseudogene)	Molecular	Gene	—	—	Emerging	Open Targets	Ensembl Open Targets
OSMR oncostatin M receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PLCG2 phospholipase C gamma 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PLEK pleckstrin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PPP1R3B protein phosphatase 1 regulatory subunit 3B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PROC protein C, inactivator of coagulation factors Va and VIIIa	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PROCR protein C receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PROS1 protein S	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTPRJ protein tyrosine phosphatase receptor type J	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
QSER1 glutamine and serine rich 1	Molecular	Gene	—	—	Emerging	Open Targets	Ensembl Open Targets
RCOR1 REST corepressor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
REEP3 receptor accessory protein 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RGS18 regulator of G protein signaling 18	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SCARA5 scavenger receptor class A member 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SERPINA1 serpin family A member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SERPINC1 serpin family C member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SERPINE1 serpin family E member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SERPINE2 serpin family E member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SH2B3 SH2B adaptor protein 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
ACETAZOLAMIDE	None	Gene-targeted
ACETYLDIGITOXIN	inhibitor	Gene-targeted
ADUCANUMAB		Gene-targeted
AFLIBERCEPT		Gene-targeted
AMPHETAMINE	None	Gene-targeted
APIXABAN		Gene-targeted
ATOGEPANT	inhibitor	Gene-targeted
BICALUTAMIDE	None	Gene-targeted
BUPROPION HYDROCHLORIDE		Gene-targeted
CARBACHOL	None	Gene-targeted
CHOLESTEROL		Gene-targeted
CHORIOGONADOTROPIN ALFA		Gene-targeted
CIPROFLOXACIN	None	Gene-targeted
CLOMIPRAMINE	None	Gene-targeted
DESLANOSIDE	inhibitor	Gene-targeted
DIAZEPAM	None	Gene-targeted
DICHLORPHENAMIDE	None	Gene-targeted
DIETHYLSTILBESTROL	None	Gene-targeted
DIGITOXIN	inhibitor	Gene-targeted
DIGOXIN	inhibitor	Gene-targeted
DONANEMAB		Gene-targeted
DONEPEZIL		Gene-targeted
DULOXETINE HYDROCHLORIDE		Gene-targeted
EPIRUBICIN	None	Gene-targeted
ERENUMAB		Gene-targeted
ETHOXZOLAMIDE	None	Gene-targeted
FENOFIBRATE MICRONIZED		Gene-targeted
FLUMAZENIL	None	Gene-targeted
FLUVASTATIN		Gene-targeted
FREMANEZUMAB		Gene-targeted
GALANTAMINE		Gene-targeted
GALCANEZUMAB		Gene-targeted
GANCICLOVIR		Gene-targeted
IMIPRAMINE	None	Gene-targeted
INDAPAMIDE	None	Gene-targeted
INDOMETHACIN	None	Gene-targeted
IRBESARTAN		Gene-targeted
ISOSORBIDE DINITRATE	None	Gene-targeted
LECANEMAB		Gene-targeted
LORAZEPAM		Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETYLDIGITOXIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ADUCANUMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
AFLIBERCEPT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
APIXABAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATOGEPANT Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BUPROPION HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CHOLESTEROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHORIOGONADOTROPIN ALFA Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DESLANOSIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIGITOXIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIGOXIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DONANEMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DONEPEZIL Repurposing	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DULOXETINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ERENUMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FENOFIBRATE MICRONIZED Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUVASTATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FREMANEZUMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
GALANTAMINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
GALCANEZUMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
GANCICLOVIR Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
IRBESARTAN Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
LECANEMAB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
LORAZEPAM Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
LUTEIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NICOTINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NICOTINE POLACRILEX Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—

Drug	Type	Phase	Evidence	Score	Sources	Links
ABELACIMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BEMIPARIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ENOXAPARIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FONDAPARINUX	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
HEPARIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
HEPARIN CALCIUM	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
HEPARIN SODIUM	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IDARUCIZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
NADROPARIN CALCIUM	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TINZAPARIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TINZAPARIN SODIUM	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
WARFARIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
GEMCITABINE HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ISOQUERCETIN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
TB-402	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ACENOCOUMAROL	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
APIXABAN	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
BETRIXABAN	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
DABIGATRAN	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
DABIGATRAN ETEXILATE	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
DALTEPARIN SODIUM	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
EDOXABAN	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
EDOXABAN TOSYLATE	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
ENOXAPARIN SODIUM	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
FLUOXETINE	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
FONDAPARINUX SODIUM	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
NORETHINDRONE	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
OPRELVEKIN	Biologic	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
PHENPROCOUMON	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
PROTEIN C CONCENTRATE (HUMAN)	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
RECOMBINANT HUMAN THROMBOPOIETIN	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
RIVAROXABAN	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets
VITAMIN K	Small molecule	Preclinical	Emerging	15	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACETAZOLAMIDE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETYLDIGITOXIN Repurposing via ATP1B1	Small molecule	Approved	Strong	95	—	DGIdb	—
ADUCANUMAB Repurposing via APOE	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
AFLIBERCEPT Repurposing via ANO2	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
APIXABAN Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
ATOGEPANT Repurposing via CALCRL	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BICALUTAMIDE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BUPROPION HYDROCHLORIDE Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CHOLESTEROL Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
CHORIOGONADOTROPIN ALFA Repurposing via APOE	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CIPROFLOXACIN Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DESLANOSIDE Repurposing via ATP1B1	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIGITOXIN Repurposing via ATP1B1	Small molecule	Approved	Strong	95	—	DGIdb	—
DIGOXIN Repurposing via ATP1B1	Small molecule	Approved	Strong	95	—	DGIdb	—
DONANEMAB Repurposing via APOE	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DONEPEZIL Repurposing via APOE	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DULOXETINE HYDROCHLORIDE Repurposing via ANO2	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIRUBICIN Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ERENUMAB Repurposing via CALCRL	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ETHOXZOLAMIDE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FENOFIBRATE MICRONIZED Repurposing via APOE	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
FLUMAZENIL Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUVASTATIN Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
FREMANEZUMAB Repurposing via CALCRL	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
GALANTAMINE Repurposing via APOE	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
GALCANEZUMAB Repurposing via CALCRL	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
GANCICLOVIR Repurposing via APOE	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
IRBESARTAN Repurposing via APOE	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ISOSORBIDE DINITRATE Repurposing via ABO	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
LECANEMAB Repurposing via APOE	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
LORAZEPAM Repurposing via APOE	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—

Natural Products

7 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Vitamin E Natural product Randomized controlled trial Effects of random allocation to vitamin E supplementation on the occurr…	Nutraceutical	Preclinical	Moderate	20	1 RCT View evidence Published literature Randomized controlled trial Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study (Circulation, 2007) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Vitamin E Natural product Randomized controlled trial Effects of random allocation to vitamin E supplementation on the occurr…	Nutraceutical	Preclinical	Emerging	10	1 RCT View evidence Published literature Randomized controlled trial Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study (Circulation, 2007) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Flavonoids Natural product Human Study Prevention of recurrent venous thrombosis and post-thrombotic syndrome.	Nutraceutical	Preclinical	Emerging	0	3 pubs View evidence CT.gov search · Cochrane · PubMed		—
Pycnogenol (Pine Bark) Natural product Human Study Prevention of recurrent venous thrombosis and post-thrombotic syndrome.	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed		—
EGCG (Epigallocatechin Gallate) Natural product Animal Study Epigallocatechin-3-gallate exerts protective effect on epithelial funct…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed		—
Glycyrrhizin Natural product Animal Study Pre-treatment with glycyrrhizin inhibited venous thrombosis.	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed		—
Blueberry Natural product In Vitro Study Blueberry phenolics reduce gastrointestinal infection of patients with…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed		—

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.